Acetazolamide in combination with a weight-reduction diet slightly improved vision in patients with idiopathic intracranial hypertension, according to a study.
The Idiopathic Intracranial Hypertension Treatment Trial, a multicenter, randomized, double-masked study, included 161 women and four men with idiopathic intracranial hypertension and mild vision loss.
Eighty-six patients received acetazolamide, and 79 patients received a placebo. Dosage was up to 4 g daily. All patients were on a low-sodium weight-reduction diet.
The primary outcome measure was the change in perimetric mean deviation at 6 months. Secondary measures were changes in papilledema grade, Visual Function Questionnaire (VFQ-25) scores, Short Form Health Survey (SF-36) scores, headache disability and weight at 6 months.
Mean perimetric mean deviation improved from –3.53 dB at baseline to –2.10 dB at 6 months in the acetazolamide group and from –3.53 dB to –2.82 dB in the placebo group; the between-group difference was statistically significant (P = .05).
Papilledema grade decreased from 2.76 to 1.45 in the acetazolamide group and from 2.76 to 2.15 in the placebo group. The difference between the groups was statistically significant (P < .001).
VFQ-25 scores improved from 82.97 to 91.30 in the acetazolamide group and from 82.97 to 84.95 in the placebo group (P = .003). SF-36 scores improved significantly more in the acetazolamide group than in the placebo group (P = .03).
Patients in the acetazolamide group lost significantly more weight than those in the placebo group (P < .001).
Both groups had similar visual acuity and headache disability.
Disclosure: See the study for a full list of all authors’ relevant financial disclosures.